Sagimet Biosciences Inc (fra:0O2) Share Price

Company Profile

Business description
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Contact
155 Bovet Road
Suite 303
San MateoCA94402
USA
T: +1 650 561-8600
https://www.sagimet.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16

Recommended

Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.

Brian Colello, CPA | 12 May 2026

Interest rates are driving a spike in property listings.

Roy Van Keulen | 12 May 2026

With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.

Mark Giarelli | 12 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,909.60	42.50	-0.47%
CAC 40	7,979.92	76.46	-0.95%
DAX 40	23,954.93	395.35	-1.62%
Dow JONES (US)	49,760.56	56.09	0.11%
FTSE 100	10,265.32	4.11	-0.04%
HKSE	26,347.91	58.93	-0.22%
NASDAQ	26,088.20	185.92	-0.71%
Nikkei 225	62,742.57	324.69	0.52%
NZX 50 Index	13,097.52	17.19	0.13%
S&P 500	7,400.96	11.88	-0.16%
S&P/ASX 200	8,670.70	40.60	-0.47%
SSE Composite Index	4,214.49	10.53	-0.25%